MA40283A - Aptamères spécifiques du récepteur tlr-4 et leurs utilisations - Google Patents

Aptamères spécifiques du récepteur tlr-4 et leurs utilisations

Info

Publication number
MA40283A
MA40283A MA040283A MA40283A MA40283A MA 40283 A MA40283 A MA 40283A MA 040283 A MA040283 A MA 040283A MA 40283 A MA40283 A MA 40283A MA 40283 A MA40283 A MA 40283A
Authority
MA
Morocco
Prior art keywords
tlr
aptamer
specific aptamers
receiver specific
methods
Prior art date
Application number
MA040283A
Other languages
English (en)
Inventor
Gómez-Chacón Gerónimo Fernández
Muñoz Víctor Manuel González
Hernández Ignacio Lizasoain
PALMA Mª ELENA MARTÍN
Yébenes Ana Moraga
Sánchez María Ángeles Moro
Original Assignee
Aptus Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptus Biotech S L filed Critical Aptus Biotech S L
Publication of MA40283A publication Critical patent/MA40283A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)

Abstract

L'invention concerne un aptamateur d'acide nucléique ayant la capacité de se lier spécifiquement et d'inhiber tlr-4, à un complexe comprenant ledit aptamère et un groupe fonctionnel, ainsi que ses compositions pharmaceutiques. L'invention concerne également des utilisations et des procédés pour détecter tlr-4 et des utilisations et des procédés pour inhiber tlr-4. Enfin, l'invention concerne également un aptamère destiné à être utilisé dans la fabrication d'un médicament pour le traitement d'une pathologie caractérisée par une augmentation de l'expression de tlr4 et / ou une augmentation de l'activation de tlr-4.
MA040283A 2014-06-24 2015-06-24 Aptamères spécifiques du récepteur tlr-4 et leurs utilisations MA40283A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430955A ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos

Publications (1)

Publication Number Publication Date
MA40283A true MA40283A (fr) 2017-05-03

Family

ID=53496661

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040283A MA40283A (fr) 2014-06-24 2015-06-24 Aptamères spécifiques du récepteur tlr-4 et leurs utilisations

Country Status (18)

Country Link
US (4) US10196642B2 (fr)
EP (1) EP3161139B1 (fr)
JP (2) JP6959738B2 (fr)
KR (1) KR102454682B1 (fr)
CN (2) CN112111495A (fr)
AU (1) AU2015279248B2 (fr)
BR (1) BR112016030172B1 (fr)
CA (1) CA2953020C (fr)
DK (1) DK3161139T3 (fr)
ES (2) ES2555160B1 (fr)
MA (1) MA40283A (fr)
MX (1) MX387405B (fr)
PL (1) PL3161139T3 (fr)
PT (1) PT3161139T (fr)
RU (1) RU2709718C9 (fr)
SI (1) SI3161139T1 (fr)
WO (1) WO2015197706A1 (fr)
ZA (1) ZA201700363B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709776B2 (en) * 2014-04-07 2020-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing outer membrane vesicles
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3494994A1 (fr) * 2017-12-07 2019-06-12 Universität zu Köln Combinaisons d'inhibiteurs de ripk1 et d'ikk pour la prévention ou le traitement de maladies immunitaires
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US20210324002A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
CA3114302A1 (fr) 2018-09-28 2020-04-02 Augmanity Nano Ltd Procedes et compositions pour la selection d'aptameres fonctionnels
AU2019352500B2 (en) 2018-10-02 2024-12-12 WearOptimo Pty Ltd Treatment delivery system
WO2020069564A1 (fr) 2018-10-02 2020-04-09 WearOptimo Pty Ltd Système pour déterminer un niveau de fluide dans un sujet biologique
WO2020069569A1 (fr) 2018-10-02 2020-04-09 WearOptimo Pty Ltd Système actionneur
WO2020230108A1 (fr) * 2019-05-16 2020-11-19 Aptatargets, S.L. Traitement d'un accident ischémique cérébral avec des aptamères ciblant tlr -4
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
US20230372407A1 (en) * 2020-06-15 2023-11-23 President And Fellows Of Harvard College Methods for modulating tlr4 signaling
CN114152599B (zh) * 2021-12-01 2023-10-13 中国农业大学 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器
CN114836425A (zh) * 2022-02-25 2022-08-02 温州医科大学附属眼视光医院 检测小胶质细胞的核酸适体及应用
AU2024206573A1 (en) 2023-01-05 2025-08-14 Merck Patent Gmbh Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
EP4716745A1 (fr) 2023-05-22 2026-04-01 Merck Patent GmbH Nouveaux aptamères antagonistes de tlr-4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
WO2001057259A1 (fr) * 2000-02-03 2001-08-09 Research Development Foundation Aptameres de signalisation capables de transduire la reconnaissance moleculaire en signal differentiel
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
CN101227922A (zh) * 2005-05-06 2008-07-23 斯克里普斯研究学院 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
US9012410B2 (en) * 2006-12-13 2015-04-21 Case Western Reserve University Method of treating intrauterine inflammation
MX2011004674A (es) * 2008-11-04 2011-05-25 Idera Pharmaceuticals Inc Modulacion de la expresion del receptor 4 tipo larga distancia por oligonucleotidos antisentido.
WO2010060030A1 (fr) * 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanostructure ligand de tlr-acide nucléique comme nouvel agent immunomodulateur et utilisations de celui-ci
WO2012118911A1 (fr) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Modulateurs des oligonucléotides de la voie de signalisation activée par les récepteurs de type toll
EP2681314B1 (fr) * 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions et procédés pour traiter des maladies et des lésions pulmonaires
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos

Also Published As

Publication number Publication date
AU2015279248A1 (en) 2017-01-12
US20230279402A1 (en) 2023-09-07
BR112016030172B1 (pt) 2022-11-01
US20170130227A1 (en) 2017-05-11
KR102454682B1 (ko) 2022-10-13
PL3161139T3 (pl) 2021-01-11
US11591603B2 (en) 2023-02-28
SI3161139T1 (sl) 2020-12-31
AU2015279248B2 (en) 2021-03-11
CN112111495A (zh) 2020-12-22
JP2020127422A (ja) 2020-08-27
MX2016016992A (es) 2017-05-03
CA2953020C (fr) 2023-01-10
WO2015197706A1 (fr) 2015-12-30
RU2016152094A (ru) 2018-07-26
BR112016030172A2 (pt) 2017-11-14
ES2555160B1 (es) 2016-10-25
RU2016152094A3 (fr) 2019-01-29
PT3161139T (pt) 2020-10-23
US20210130830A1 (en) 2021-05-06
ES2555160A1 (es) 2015-12-29
US20190211334A1 (en) 2019-07-11
JP2017527260A (ja) 2017-09-21
CN106459980A (zh) 2017-02-22
EP3161139B1 (fr) 2020-07-22
ES2825106T3 (es) 2021-05-14
DK3161139T3 (da) 2020-10-19
RU2709718C9 (ru) 2020-02-06
MX387405B (es) 2025-03-18
CN106459980B (zh) 2020-11-03
US10196642B2 (en) 2019-02-05
RU2709718C2 (ru) 2019-12-19
ZA201700363B (en) 2018-11-28
CA2953020A1 (fr) 2015-12-30
US10808252B2 (en) 2020-10-20
JP6959738B2 (ja) 2021-11-05
KR20170021298A (ko) 2017-02-27
EP3161139A1 (fr) 2017-05-03

Similar Documents

Publication Publication Date Title
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MA38406B1 (fr) Virus de la maladie de newcastle et leurs utilisations
WO2018069500A3 (fr) Anticorps anti-lag-3 et compositions
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
EA201792047A1 (ru) Новые соединения
EA201491656A1 (ru) Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения
MA44637A1 (fr) Composes hétérocycliques et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
PH12016501307A1 (en) Compounds
PH12018500578A1 (en) Methods of treating inflammatory diseases
MA38567A1 (fr) Variantes de pertuzumab et leur évaluation
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
MX387405B (es) Aptámeros específicos de tlr-4 y usos de los mismos.
EA201591379A1 (ru) Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
HK1207970A1 (en) Agents for influenza neutralization
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
WO2018071504A3 (fr) Méthodes de traitement de maladies
EA201791845A1 (ru) Твердые формы менахинолов
AU2017261919A1 (en) Fat and medical uses thereof
FR3074421B1 (fr) Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
EP3295947A4 (fr) Composition pharmaceutique pour la prévention et le traitement de la maladie pulmonaire obstructive chronique contenant, comme principe actif, un extrait, une fraction ou une fraction active deflos magnoliae
EA201790117A1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение